Biotech Values

[ghmm]

Dew,

These results look unspectacular to me. I don't know median survival stats for NSCLC off hand though so can't say for sure. Do you think it speaks to the limited efficacy of Immunotherapy in general?

I noticed the patients were stage 1B/II. I know United (OvaRex) while looking at Stage III/IV Ovarian cancer wanted optimal responders to surgery and low (but present) CA-125 levels. In retrospective analysis it also seemed that certain patients had extremely long PFS and overall survival and others had no benefit.

I'm not decided yet on Immunotherapies. It seems it may have a very meaningful benefit for a subset of patients but perhaps not a majority of them.